A new report by visiongain predicts the world market for biosimilar drugs will be worth $2,445m in 2013, growing by more than 20% from 2012. In 2013 it will account for around 2% of the overall biologics (biological drugs) market. That study forecasts rapid growth to 2023 for the global biosimilars market. The launch of more biosimilars worldwide, but particularly in the US and EU, will drive that sales growth. These predictions and other forecasts appear in Biosimilars and Follow-On Biologics: World Market 2013-2023, published in April 2013.
Fastest growth will be in the biosimilar monoclonal antibodies and insulin submarkets. Two companies – Celltrion and Hospira – submitted biosimilar antibody approval applications to the European Medicines Agency (EMA) in 2012. Those products will be launched in the EU in 2014, visiongain predicts. From 2014, many companies will try to launch monoclonal antibody biosimilars, with most targeting Roche’s Rituxan (rituximab) and Herceptin (trastuzumab), and Remicade (infliximab, J&J/Merck & Co./Mitsubishi Tanabe) for competition. By 2023, biosimilar monoclonal antibodies (mAbs) and insulin products will account for 57% of the global biosimilars market, the study also predicts.
Visiongain forecasts steady growth to 2023 for other segments of the biosimilars market. Biosimilar erythropoietins and filgrastim products are already available in the EU, Japan and other developed markets and achieve limited revenues compared with their reference biologics. The launch of these biosimilars in the US will drive growth from 2014, as will the launch worldwide of second generation filgrastim (pegfilgrastim) and epoetin alpha (darbepoetin alpha) biosimilars. The biosimilar human growth hormone submarket will be the slowest-growing of the leading market sectors. Sandoz’s growth hormone biosimilar, Omnitrope (somatropin) was the first biosimilar launched in many major markets, from 2004 onwards. That drug has achieved limited market penetration, though.
Richard Lang, a pharmaceutical market analyst for visiongain, said: “Many companies are interested in entering the biosimilars market. These drugs offer a simpler way to launch biopharmaceuticals, compared with developing novel biologics. Big pharma companies, such as Pfizer, Merck & Co. and Boehringer Ingelheim, have invested in this area in recent years. Many of these companies are focusing on biosimilar monoclonal antibody development – those three companies have clinical-stage candidates in that sector.
“Not all biosimilar development programmes will be successful, though. Biologics and biosimilars are large, complex molecules requiring long and expensive development and manufacturing. The recent release of development guidelines by regulatory agencies in markets worldwide will increase the success rate of biosimilar development. However, commercialising biosimilars is as challenging as developing them. Companies will need to brand and market their biosimilars in a similar way to novel drugs, engaging key stakeholders such as doctors, healthcare payers and patients, to achieve high market penetration.”
Visiongain’s new report forecasts the world biosimilars market to 2023, as well as providing forecasts for its seven leading segments:
- Monoclonal antibodies (mAbs)
- Insulins – with sub forecasts for human insulin, fast-acting and long-acting analogues
- Interferons – with sub forecasts for alpha and beta interferon
- Erythropoietin (EPO)
- Follicle stimulating hormone (FSH).
That study also forecasts leading national markets for biosimilars. In 2012 emerging markets accounted for the majority of global biosimilar revenues. Biosimilars were first launched in these markets more than two decades ago. Hundreds of biosimilars are marketed in China, which was the leading national market in 2012. There, as in other leading emerging countries, such as India, the market is fragmented, with few companies achieving revenue over $10m. Growth in developed markets will be much faster than in emerging markets between 2013 and 2023. In 2012 the US, EU and Japan accounted for just 20% of the global biosimilars market. Patent expiries for blockbuster biologics between 2013 and 2017 will drive growth in those national markets.
Biosimilars and Follow-On Biologics: World Market 2013-2023 adds to visiongain’s portfolio of market analysis for leading sectors of the biopharmaceutical industry. Visiongain is a business information provider based in London, UK.
For sample pages and further information concerning the visiongain report the Biosimilars and Follow-On Biologics: World Market 2013-2023 please visit
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.